Wedbush Boosts Target on Outperform-Rated Oncothyreon (ONTY) to $31 Ahead of STIMUVAX Phase III Data
Tweet
Share
E-mail
Get Alerts ONTY Hot Sheet
Price: $1.21 --0%
Rating Summary:
7 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 14
Rating Summary:
7 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 14
Join SI Premium – FREE
Oncothyreon Inc. (Nasdaq: ONTY) is up about 7 percent Wednesday, following a price target raise at Wedbush.
The firm moved its target from $15 to $31, maintaining an Outperform rating, following a look at STIMUVAX.
Wedbush thinks that the next interim look for STIMUVAX -- expected in Q112 -- will have the Phase III trial achieving a pre-specified threshold for early stopping.
Wedbush comments, "We view the risk reward opportunity for ONTY as highly asymmetric ($2-4/share downside [futility/continue], $25/share upside). Based upon our assumption that the P value to trigger an early stop at this second interim is <= 0.001, and that at this point in the Study, the Hazard value is roughly 0.65, our calculations suggest that with the 529 events there is better than a 90% probability that the Study will hit the early stopping success threshold."
Oncothyreon recently provided an update on Phase I results from studies of PX-866 in combination with either docetaxel or cetuximab; Phase II results expected at ASCO 2012. Data showed PX-866 in combo with cetuximab showed a disease control rate of 88% and an ORR of 50% vs. historical single agent ORR of 12.5% and resulted in no addition toxicity. Further, PX-866 in combo with docetaxel showed a disease control rate of 75% in 43 pts with advanced cancer where docetaxel is the standard of care.
Finally, Wedbush said, "PX-866 continues to be well tolerated in combination at the single-agent dose with both docetaxel and cetuximab; no DLTs were observed."
For an analyst ratings summary and ratings history on Oncothyreon click here. For more ratings news on Oncothyreon click here.
Shares of Oncothyreon closed at $6.41 yesterday.
The firm moved its target from $15 to $31, maintaining an Outperform rating, following a look at STIMUVAX.
Wedbush thinks that the next interim look for STIMUVAX -- expected in Q112 -- will have the Phase III trial achieving a pre-specified threshold for early stopping.
Wedbush comments, "We view the risk reward opportunity for ONTY as highly asymmetric ($2-4/share downside [futility/continue], $25/share upside). Based upon our assumption that the P value to trigger an early stop at this second interim is <= 0.001, and that at this point in the Study, the Hazard value is roughly 0.65, our calculations suggest that with the 529 events there is better than a 90% probability that the Study will hit the early stopping success threshold."
Oncothyreon recently provided an update on Phase I results from studies of PX-866 in combination with either docetaxel or cetuximab; Phase II results expected at ASCO 2012. Data showed PX-866 in combo with cetuximab showed a disease control rate of 88% and an ORR of 50% vs. historical single agent ORR of 12.5% and resulted in no addition toxicity. Further, PX-866 in combo with docetaxel showed a disease control rate of 75% in 43 pts with advanced cancer where docetaxel is the standard of care.
Finally, Wedbush said, "PX-866 continues to be well tolerated in combination at the single-agent dose with both docetaxel and cetuximab; no DLTs were observed."
For an analyst ratings summary and ratings history on Oncothyreon click here. For more ratings news on Oncothyreon click here.
Shares of Oncothyreon closed at $6.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Summit Insights Downgrades Silicon Labs (SLAB) to Hold, 'expect its stock to be an inline performer'
- Craig-Hallum Assumes DiaMedica Therapeutics Inc. (DMAC) at Buy
- Root, Inc. (ROOT) PT Raised to $70 at Keefe, Bruyette & Woods
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
